Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?

BJU International

Volumn 104, Issue 2, 2009, Pages 170-174

  Dobruch, Jakub ^a,b   Herr, Harry ^c  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b Department of Urology ^*  (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder tumour; Single intraoperative chemotherapeutic instillation; Transurethral resection

Indexed keywords

CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; MITOMYCIN C;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 67650575641     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08654.x     Document Type: Short Survey

References (20)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005 16 : 481 8
3. Babjuk M, Oosterlinck W, Sylvester R, Kassinen E, Böhle A, Palou J. Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Association of Urology Guidelines. Arnhem, the Netherlands : European Association of Urology, 2008 : 3 21
4. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007 178 : 2314 30
5. Joudi FN, Smith BJ, O'Donnell MA, Konety BR. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology 2003 62 : 1083 8
6. Gudjonsson S, Adell L, Merdasa F et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicenter study. Eur Urol 2009 [Epub ahead of print]. DOI:10.1016/j.eururo.2009.01.006
7. Rajala P, Liukkonen T, Raitanen M et al. Transurethral resection with perioperative instillation on interferon-α or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study - FinnBladder III. J Urol 1999 161 : 1133 6
8. Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmäng S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 2008 179 : 101 6
9. Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 1997 79 : 731 5
10. Oosterlinck W, Kurth KH, Schroder FH, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993 149 : 749 52
11. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999 161 : 1120 3
12. Tolley DA, Parmar MK, Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996 155 : 1233 8
13. Okamura K, Ono Y, Kinukawa T et al. Randomized study of single early instillation of (2′′R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002 94 : 2363 8
14. Sylvester RJ, Oosterlinck W, van der Meijden A. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004 171 : 2186 90
15. Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 1983 129 : 505 9
16. Cai T, Nesi G, Tinacci G et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 2008 180 : 110 5
17. Gofrit ON, Pode D, Lazar A, Katz R, Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 2006 49 : 303 7
18. Donat SM, North A, Dalbagni G, Herr HW. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol 2004 171 : 636 9
19. Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol 2007 178 : 1201 5
20. Herr HW, Donat SM, Dalbagni G. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 2002 168 : 978 80